EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Amgen's Enterprise Value is $170,489 Mil.
Amgen's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $9,685 Mil. Therefore, Amgen's EV-to-FCF for today is 17.60.
The historical rank and industry rank for Amgen's EV-to-FCF or its related term are showing as below:
AMGN'
s EV-to-FCF Range Over the Past 10 Years
Min: 10.97 Med: 15.48 Max: 22.08
Current: 17.6
During the past 13 years, the highest EV-to-FCF of Amgen was 22.08. The lowest was 10.97. And the median was 15.48.
AMGN's EV-to-FCF is ranked better than 60.59% of 510
companies
in the Drug Manufacturers industry
Industry Median: 23.15
vs AMGN: 17.60
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2023-09-25), Amgen's stock price is $267.70.
Amgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $14.830. Therefore, Amgen's PE Ratio for today is 18.05.
Amgen EV-to-FCF Historical Data
The historical data trend for Amgen's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
EV-to-FCF
12.05
19.17
15.70
18.00
19.34
Amgen Quarterly Data
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
EV-to-FCF
19.09
16.39
19.34
21.14
15.08
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen EV-to-FCF Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Amgen's EV-to-FCF falls in comparison to its industry or sector. The grey bar indicates the EV-to-FCF's extreme value range as defined by GuruFocus.
Amgen's current Enterprise Value is $170,489 Mil.
Amgen's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9,685 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (NAS:AMGN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Amgen's share price for today is $267.70.
Amgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.830.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Amgen EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Amgen's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
1.71(0.63%) Volume: 1,855,634 11:09PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
AMGN has been successfully added to your 
